DEVELOPMENT OF GEL-LOADED BASED MICROSPONGES OF CLARITHROMYCIN FOR THE TREATMENT OF TOPICAL DELIVERY

Authors

  • SUNNY DHIMAN School of Pharmacy, Abhilashi University, Mandi, HP India
  • NISHANT SHARMA School of Pharmacy, Abhilashi University, Mandi, HP India
  • REENA THAKUR School of Pharmacy, Abhilashi University, Mandi, HP India
  • INDER KUMAR School of Pharmacy, Abhilashi University, Mandi, HP India https://orcid.org/0000-0002-7295-5450
  • BHUMIKA THAKUR Shiva Institute of Pharmacy, Bilaspur, HP India
  • ANKITA SHARMA Shiva Institute of Pharmacy, Bilaspur, HP India
  • VANDANA THAKUR Abhilashi College of Pharmacy, Nerchowk, Mandi HP India
  • KIRAN KUMARI Abhilashi College of Pharmacy, Nerchowk, Mandi HP India

DOI:

https://doi.org/10.22159/ijap.2022v14i4.45102

Keywords:

Microsponges, Clarithromycin, Eudragit RS 100, Acne Vulgaris, Controlled release

Abstract

Objective: The purpose of the present study aims to design a novel drug delivery system containing clarithromycin microsponges and to prepare microsponge gel.

Methods: The microsponges were prepared by quasi-emulsion solvent diffusion method using polymer eudragit RS-100. All the formulated microsponges were subjected to various evaluation parameters such as production yield, encapsulation efficiency, particle size analysis, and in vitro drug release study.

Results: In vitro drug release of all the formulations was found to be 47.36% to 87.32%. Formulations F2, F3, and F4 show the best drug release from all formulations within 480 min. The optimized microsponge formulations F2, F3, and F4 were further formulated as gel formulations for topical delivery. Prepared gel was evaluated for physical parameters like pH, spreadability, viscosity, drug content, in vitro diffusion study, and stability study. All gel formulations showed drug release of 63.18±0.52%, 76.4±0.51%, and 72.93±0.42% from formulations GF1, GF2, and GF3, respectively, within 480 min. The microsponge gel formulation GF2 showed the controlled release of clarithromycin for 480 min, which was 76.4±0.51%. The stability study shows no significant changes in all parameters.

Conclusion: With the revealed results by different evaluation parameters, it is concluded that the microsponges drug delivery system has become a highly competitive and rapidly evolving technology and more and more research is carried out to optimize the cost-effectiveness and efficacy of the therapy.

Downloads

Download data is not yet available.

References

Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):1-29. doi: 10.1038/s41598-020-62715-3.

Ak M. A comprehensive review of acne vulgaris. J Clin Pharm. 2019;1:17-45.

Jay C, Vary Jr. Selected disorders of skin appendages-acne, alopecia, hyperhidrosis. Med Clin. 2015;99(6):1195–211.

Taylor M, Gonzalez M, Porter R. Pathways to inflammation: acne pathophysiology. Eur J Dermatol. 2011;21(3):323-33. doi: 10.1684/ejd.2011.1357.

Mahmood NF, Shipman AR. The age-old problem of acne. Int J Womens Dermatol. 2017;3(2):71-6. doi: 10.1016/j.ijwd.2016.11.002. PMID 28560299.

Sharma M, Gupta AK, Minocha S. A review on acne. J Biomed Pharm Res. 2015;4(1):121-6.

Charde YM, Sharma PH, Choudhary NG. Development and evaluation of herbal formulation for the treatment of acne. Int J Pharm Sci Res. 2014;5(6):2250-60.

Pawan SA, Prashant BP. A new era in topical formulations–Microsponge drug delivery system. Int J Pharm Sci Res. 2016;7(7):2756-61.

Lohot S, Yadav A, Kakade S, Veer V, Bhosale A. A review on microsponges: a novel drug delivery system. J Curr Pharm Res. 2020;10(2):3615-29.

Baibhav J, Gurpreet S, Rana AC. Development and characterization of clarithromycin emulgel for topical delivery. Int J Drug Dev Res. 2012;4(3):310-23.

Takemori N, Nakamura M, Kojima M, Eishi Y. Successful treatment in a case of Propionibacterium acnes-associated sarcoidosis with clarithromycin administration: a case report. J Med Case Rep. 2014;8:15. doi: 10.1186/1752-1947-8-15, PMID 24428939.

Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001;429(1-3):209-29. doi: 10.1016/s0014-2999(01)01321-8, PMID 11698042.

Nangude S, Vite M, Chugh N. Development of UV spectrophotometric method for estimation of clarithromycin in pharmaceutical dosage form by using folin-ciocalteu reagent. Int J Pharm Chem Sci. 2013;2(2):640-2.

Obiedallah MM, Abdel Mageed AM, Elfaham TH. Ocular administration of acetazolamide microsponges in situ gel formulations. Saudi Pharm J. 2018;26(7):909-20. doi: 10.1016/j.jsps.2018.01.005, PMID 30416345.

Syal S, Pandit V, Ankalgi AD, Verma CPS, Ashawat MS. Formulation and evaluation of microsponges gel of havan ash for the treatment of acne. J Drug Delivery Ther. 2020;10(6):74-85. doi: 10.22270/jddt.v10i6.4380.

Sharma P. Formulation and evaluation of gel-loaded microsponges of roxithromycin for topical drug Deliv. IOSR J Pharm. 2019;9(5):14-22.

Dibyalochan M, Bakshi V, Rashaid MB. Design and in vitro characterization of betamethasone microsponge loaded topical gel. Int J Pharm Res Health Sci. 2016;4(2):1124-9.

Osmani RAM, Aloorkar NH, Thaware BU, Kulkarni PK, Moin A, Hani U. Microsponge based drug delivery system for augmented gastroparesis therapy: formulation development and evaluation. Asian J Pharm Sci. 2015;10(5):442-51. doi: 10.1016/j.ajps.2015.06.003.

Pande VV, Kadnor NA, Kadam RN, Upadhye SA. Fabrication and characterization of sertaconazole nitrate microsponge as a topical drug delivery system. Indian J Pharm Sci. 2015;77(6):675-80. doi: 10.4103/0250-474x.174986. PMID 26997694.

Jain V, Singh R. Design and characterization of colon-specific drug delivery system containing paracetamol microsponges. Arch Pharm Res. 2011;34(5):733-40. doi: 10.1007/s12272-011-0506-4, PMID 21656358.

Moin A, Deb TK, Osmani RA, Bhosale RR, Hani U. Fabrication, characterization, and evaluation of microsponge delivery system for facilitated fungal therapy. J Basic Clin Pharm. 2016;7(2):39-48. doi: 10.4103/0976-0105.177705, PMID 27057125.

Swetha CH, Velmurugun S, Reddy GN. Formulation and evaluation of clarithromycin topical gel. Int J Drug Dev Res. 2013;5(4):194-202.

Devi N, Kumar S, Prasad M, Rao R. Eudragit RS100 based microsponges for dermal delivery of clobetasol propionate in psoriasis management. J Drug Deliv Sci Technol. 2020;55:101347. doi: 10.1016/j.jddst.2019.101347.

Thavva V, Baratam SR. Formulation and evaluation of terbinafine hydrochloride microsponge gel. Int J Appl Pharm. 2019;11(6):78-85. doi: 10.22159/ijap.2019v11i6.32502.

Baibhav J, Gurpreet S, Rana AC, Seema S. Development and characterization of clarithromycin emulgel for topical delivery. Int J Drug Dev Res. 2012;4(3):310-23.

Abd Alhammid SN. Enhancement of the solubility and the dissolution rate of candesartan cilexetil using microsponge technology. Asian J Pharm Clin Res. 2018;11(9):385-90. doi: 10.22159/ajpcr.2018.v11i9.26816.

Thireesha B, Prasad AR, Peter P L H. Formulation and evaluation of lornoxicam microsponges using eudragit RS 100 and eudragit RSPO. Asian J Pharm Clin Res. 2018;11(10):217-21. doi: 10.22159/ajpcr.2018.v11i10.26861.

Published

07-07-2022

How to Cite

DHIMAN, S., SHARMA, N., THAKUR, R., KUMAR, I., THAKUR, B., SHARMA, A., THAKUR, V., & KUMARI, K. (2022). DEVELOPMENT OF GEL-LOADED BASED MICROSPONGES OF CLARITHROMYCIN FOR THE TREATMENT OF TOPICAL DELIVERY. International Journal of Applied Pharmaceutics, 14(4), 171–177. https://doi.org/10.22159/ijap.2022v14i4.45102

Issue

Section

Original Article(s)

Most read articles by the same author(s)